Sun, Nov 23, 2014, 8:13 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • mt_cervin mt_cervin Feb 22, 2013 2:13 PM Flag

    Boosting revenues: price + survival + tolerability

    Genentech's Ed Lang: “The monthly cost of Kadcyla in the United States is $9,800. The estimated cost of a course of Kadcyla is approximately $94,000. This is based on people taking Kadcyla for 9.6 months. When pricing Kadcyla, we considered a variety of factors including that cost of the combination of Tykerb and Xeloda (approximately $10,460 per month) which is the current standard treatment in this line of therapy and the comparator in the pivotal EMILIA study.

    I.e. monthly Kadcyla price doubles that of Herceptin ($9,800 vs. $4,500) + prolongs survivval in mBC (lived a median of 5.8 months longer [overall survival] than Tykerb + Xeloda in 2nd line mBC) + is better tolerated than Tykerb + Xeloda as standard of care in 2nd line mBC (i.e. less drug discontinuation)

    As a reference, Herceptin sales in 1st line mBC are $2bn and no sales in 3rd line:
    pricing and treatment duration in mBC alone make Kadcyla a USD4bn drug

9.84+0.16(+1.65%)Nov 21 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.